Patent suit against Biocon- Keeping Galvus in check…

The most famous drug for diabetes, Galvus also known as Vildagliptin is under patent litigation. Swiss drug maker Novartis has filed an infringement proceeding against Biocon, the Bangalore-based Company and Asia’s largest insulin maker on Galvus or Vildagliptin, a DPP4 inhibitor class of drugs used to treat type-2 diabetes. Novartis filed the case on 27…